ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,703Medicare Part D Prescriptions Filled, Including Refills

Rank: 116 out of 337

$305K Total Retail Price of All Prescriptions

Rank: 153 out of 337

368 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
19% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 368 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

7% of this provider’s 368 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 7,008 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$40 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
SIMVASTATIN 369 344 1 1
OMEPRAZOLE 331 278 2 4
LISINOPRIL 308 271 3 2
FUROSEMIDE 241 225 4 8
METFORMIN HCL 233 220 5 12
ATORVASTATIN CALCIUM 221 221 6 7
LEVOTHYROXINE SODIUM 212 197 7 5
HYDROCHLOROTHIAZIDE 200 191 8 9
AMLODIPINE BESYLATE 190 167 9 3
ZOLPIDEM TARTRATE 150 126 10 23
METOPROLOL TARTRATE 149 144 11 6
SERTRALINE HCL 127 116 12 18
GLIMEPIRIDE 124 124 13 55
ALLOPURINOL 122 110 14 28
HYDROCODONE-ACETAMINOPHEN 112 63 S3 15 13
ATENOLOL 109 104 16 10
TRAMADOL HCL 106 91 17 32
CITALOPRAM HBR 101 86 18 17
LOVASTATIN 99 87 19 24
FENOFIBRATE 98 86 20 48
TAMSULOSIN HCL 92 83 21 25
METOPROLOL SUCCINATE 91 80 22 21
ALENDRONATE SODIUM 82 82 23 19
TRAZODONE HCL 81 68 24 16
ZETIA 78 78 25 89
CIPROFLOXACIN HCL 75 69 26 71
GLIPIZIDE 74 67 27 45
LOSARTAN POTASSIUM 73 69 28 15
CRESTOR 72 67 29 29
KLOR-CON M20 72 60 29 65
MELOXICAM 71 67 31 54
WARFARIN SODIUM 70 70 32 11
GABAPENTIN 69 66 33 20
FLUTICASONE PROPIONATE 67 57 34 34
ACETAMINOPHEN-CODEINE 65 65 S3 35 142
LOSARTAN-HYDROCHLOROTHIAZIDE 62 62 36 60
CLOPIDOGREL 62 58 36 42
IBUPROFEN 61 56 38 64
ISOSORBIDE MONONITRATE ER 60 60 39 70
POTASSIUM CHLORIDE 57 57 40 62
PANTOPRAZOLE SODIUM 57 57 40 36
DONEPEZIL HCL 53 41 42 22
PREDNISONE 52 52 43 40
VERAPAMIL ER 50 50 44 77
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 23, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.